11–15-mer synthetic olps corresponding to each 25-mer neoantigen vaccine peptide (GenScript corporation)
90
Structured Review
GenScript corporation
11–15-mer synthetic olps corresponding to each 25-mer neoantigen vaccine peptide
11–15 Mer Synthetic Olps Corresponding To Each 25 Mer Neoantigen Vaccine Peptide, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/11%E2%80%9315-mer+synthetic+olps+corresponding+to+each+25-mer+neoantigen+vaccine+peptide/11+15+mer+synthetic+olps+corresponding+to+each+25+mer+neoantigen+vaccine+peptide/pm40346292-211-9-12
Average 90 stars, based on 1 article reviews
11–15 Mer Synthetic Olps Corresponding To Each 25 Mer Neoantigen Vaccine Peptide, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/11%E2%80%9315-mer+synthetic+olps+corresponding+to+each+25-mer+neoantigen+vaccine+peptide/11+15+mer+synthetic+olps+corresponding+to+each+25+mer+neoantigen+vaccine+peptide/pm40346292-211-9-12
Average 90 stars, based on 1 article reviews
11–15-mer synthetic olps corresponding to each 25-mer neoantigen vaccine peptide - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
other:Article Title: Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial. Article Snippet: Features of constrained adaptive immunity and high neoantigen burden have been correlated with response to immune checkpoint inhibitors (ICIs).. In an attempt to stimulate antitumor immunity, we evaluated atezolizumab (anti-programmed cell death protein 1 ligand 1) in combination with PGV001, a personalized neoantigen vaccine, in participants with urothelial cancer.. The primary endpoints were feasibility (as defined by neoantigen identification, peptide synthesis, vaccine production time and vaccine administration) and safety. |